Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Estimates By $0.26 EPS

Citius Oncology (NASDAQ:CTOR) posted its earnings results on Friday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.26), FiscalAI reports. The company had revenue of $1.67 million for the quarter, compared to analyst estimates of $7.00 million.

Citius Oncology Stock Down 2.1%

CTOR stock traded down $0.02 during trading on Friday, reaching $0.96. The stock had a trading volume of 25,246 shares, compared to its average volume of 230,932. Citius Oncology has a 1-year low of $0.49 and a 1-year high of $6.19. The company has a current ratio of 0.83, a quick ratio of 0.32 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $85.04 million, a P/E ratio of -3.11 and a beta of 3.56. The firm has a fifty day moving average price of $0.81 and a 200 day moving average price of $1.07.

Hedge Funds Weigh In On Citius Oncology

A number of institutional investors have recently added to or reduced their stakes in CTOR. Armistice Capital LLC acquired a new position in Citius Oncology in the 3rd quarter worth $15,582,000. Jane Street Group LLC bought a new stake in shares of Citius Oncology in the 2nd quarter worth about $465,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Citius Oncology in the 4th quarter worth about $104,000. Geode Capital Management LLC grew its position in shares of Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock valued at $220,000 after buying an additional 52,875 shares during the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Citius Oncology during the 3rd quarter valued at about $36,000. Institutional investors and hedge funds own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.